Diffusely invasive glioma, the most common and malignant primary brain tumor, comprises a diverse group of diseases. These tumors range from lower-grade astrocytomas and oligodendrogliomas (grades II and III) to the deadly glioblastoma (GBM, grade IV) when diagnosed based on the current World Health Organization (WHO) classification.
1 GBM has historically been treated as a single disease on the basis of histological criteria; however, advances in molecular technology and the advent of next-generation sequencing have revealed significant heterogeneity both within and among tumors. In 1999, the NCI Director’s Challenge asked “the scientific community to harness the power of comprehensive molecular analysis technologies to make the classification of tumors vastly more informative.” In response, The Cancer Genome Atlas (TCGA) and others identified mutational drivers in GBM and classified tumors into subtypes according to gene expression. Alterations in tumor suppressors such as
CDKN2A,
TP53, and
PTEN and oncogenes including
EGFR were among those most frequently found, delineating signaling pathways commonly affected in this disease.
2 Additionally, tumors harboring point mutations in the genes encoding isocitrate dehydrogenase (
IDH1 or
IDH2) were found to be associated with longer survival than their
IDH wild-type (IDHwt) counterparts.
3 Because of these newly discovered genomic alterations and their implications for the clinic, the 2016 WHO classification of central nervous system tumors was historic in that it included both molecular and histological criteria for the diagnosis of GBM.
1